Top

European Child & Adolescent Psychiatry

Published in:

01-12-2006 | BRIEF REPORT

Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers

Four case reports

Authors: F. Neslihan İnal Emiroglu, MD, Özlem Gencer, MD, Aylin Özbek, MD

Published in: European Child & Adolescent Psychiatry | Issue 8/2006

Abstract

This report was aimed to evaluate the efficacy of olanzapine treatment as an adjunct therapy to mood stabilizers in the treatment of four adolescents responding insufficiently to mood stabilizers. All patients were diagnosed with bipolar I disorder according to DSM IV criteria. YMRS (Young mania rating scale) and CGI (Clinical global impression, improvement and therapeutic effectiveness scales) were used to evaluate overall response of the episode to the drugs. All patients with no adequate response to mood stabilizers did respond to adjunctive olanzapine treatment (10–30 mg/per day). It has been suggested that antipsychotics may be useful as an adjunct to mood stabilisers in bipolar disorder. However, further research is warranted regarding the use of atypical antipsychotics in children and adolescents.

Tollefson GD, Sanger TM, Lu MK, Thiema ME (1998) Depressive signs and symptoms in schizophrenia—a prospective blinded trial of olanzapine and halloperidol. Arch Gen Pscyhiatry 55: 250–258CrossRef

Tohen M, Sanger T, Tollefson GD, Mc Elroy SL (1997) Olanzapine versus halloperidol in the treatment of schizoaffective bipolar patients. In: Annual Meeting New Research Program and Abstracts. American Psychiatric Association, Washington, DC, pp 123–124

Tohen M, Jacobs TG, Meyers TM (2000) Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. Program and Abstracts of the 153rd Annual American Psychiatric Association Meeting May 13–18, Chicago, Illinois

Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Tomo V ,Rater M, Tarazi RA (2001) A prospective open-label treatment trial of olanzapine monothreapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239–250PubMedCrossRef

Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J (2005) Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-aged children. Biol Psychiatry 58:589–594PubMedCrossRef

Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensivity. Br J Psychiatry 133:429–435PubMedCrossRef

Guy W (1976) ECDEU Assesment Manual for Psychopharmacology. Revised: US Department of Health, Education and Welfare, Rockville, MD

Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, Martinez-Aran A, Gasto C, Tohen M (2001) Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 21:469–473PubMedCrossRef

Wozniak J, Biederman J, Mundy E, Mennin D, Faraone V (1995) A pilot family study of childhood-onset mania. J Am Acad Child Adolesc Psychiatry 34:1577–1583PubMedCrossRef

10.

Tohen M, Sanger TM, Mc Elroy SL, Tollefson GD, Chengappe RKN (1999) Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 156:702–709PubMed

11.

Tohen M, Jacobs T, Grundy SL, Mc Elroy SL, Banov MC, Janicak PG, Sanger TM, Risser G, Zhang F, Toma V (2000) Efficacy of olanzapine in acute bipolar mania; a double-blind placebo controlled study. The olanzipine HGGW study group. Arch Gen Pscyhiatry 57:841–849CrossRef

12.

Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR (2004) Relapse prevention in bipolar I disorder: 18 month comparison of olanzapine plus mood stabiliser versus mood stabiliser alone. Br J Psychiatry 184:337–345PubMedCrossRef

13.

Kane JM (1999) Tardive dyskinesia in affective disorders. J Clin Psychiatry 60:43–47PubMed

Title: Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers
Four case reports
Authors: F. Neslihan İnal Emiroglu, MD
Özlem Gencer, MD
Aylin Özbek, MD
Publication date: 01-12-2006
Publisher: Steinkopff-Verlag
Published in: European Child & Adolescent Psychiatry / Issue 8/2006
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-006-0552-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers

Four case reports

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2006

Risk factors for the development of emotional and behavioural problems in children born to drug-dependent mothers

Increased mRNA levels of the mitochondrial complex I 75-kDa subunit

A package of interventions to reduce school dropout in public schools in a developing country

Duloxetine for childhood depression with pain and dissociative symptoms

Evaluating mental health services in a Greek community

Long-acting medications for the hyperkinetic disorders